The Effect of Adjuvant Therapy for Curatively Resected Extrahepatic Bile Duct Cancer.
- Author:
Won Shik HAN
1
;
Sang Jae PARK
;
Sun Whe KIM
;
Ki Hwan KIM
;
Sung Whan HA
;
Yung Jue BANG
;
Noe Kyeong KIM
;
Yong Hyun PARK
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Extrahepatic bile duct cancer;
Adjuvant therapy;
Radiotherapy;
Chemotherapy
- MeSH:
Bile Ducts, Extrahepatic*;
Drug Therapy;
Fluorouracil;
Hepatic Duct, Common;
Humans;
Lymph Nodes;
Maintenance Chemotherapy;
Multivariate Analysis;
Radiotherapy;
Radiotherapy, Adjuvant;
Recurrence;
Retrospective Studies;
Seoul;
Survival Rate
- From:Journal of the Korean Cancer Association
1999;31(6):1253-1260
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was attempted to evaluate the effect of adjuvant radiotherapy and chemotherapy after curative resection of extrahepatic bile duct cancer. MATERIALS AND METHODS: The authors performed a retrospective analysis of 57 patients with extrahepatic bile duct cancer not involving the hepatic duct confluence and curatively resected at Seoul National University Hospital between 1990 and 1995. Resection margins of all cases were confirmed pathologically as free of cancer cells. Among 57 patients, 29 received adjuvant therapy. Total 4000 cGy of external beam radiation was delivered to each. 5-fluorouracil (5-FU) was administered as a radiosensitizer. After 4 weeks of radiation therapy, 5-FU maintenance chemotherapy was started and given every 4 weeks up to 12 cycles or until evidence of relapse. RESULTS: The overall median survival of 57 patients was 24 months. I- and 2-year overall survival rate was 73.7 and 52.6%. There was no difference in overall survival rate between adjuvant therapy group (n=29) and operation-only group (n 28). We tried to evaluate the effect on survival of adjuvant therapy according to lymph node status. Patients of Tl stage were excluded from analysis. Adjuvant therapy had no survival benefit in the lymph node positive group. But in the lymph node negative group, 1- and 2-year survival rate of patients who underwent adjuvant therapy were 89.5% and 68.4% whereas 1 and 2-year survival rate of patients in operation-only group were 57.9% and 36.8%, which was statistically significant (p=0.0278, 0.0472). And by multivariate analysis, the survival improvement of 1- and 2-year survival rate in adjuvant therapy group was due to adjuvant therapy itself. CONCLUSION: Our trial of external beam radiotherapy combined with 5-FU chemotherapy after curative resection of extrahepatic bile duct cancer did not show improved overall survival. However the 1- and 2-year survival rate of patients with negative lymph node and advanced T stage ( > T 1) were improved in adjuvant therapy group, so adjuvant therapy may give survival benefit to a certain patient group with negative lymph node.
